News from Asia

Tue Nov 1

Grand Pharma’s Global Innovative Product STC3141 Achieved the Clinical Endpoint of The Phase Ib Clinical Trial for the Treatment of ARDS in China

According to the data analysis of the clinical trial, in the primary endpoint of the study, STC3141 did not suggest any potential serious safety problems or unexpected results in the overall safety profile, showing favorable safety and tolerance;
In the analysis of the secondary endpoint of efficacy, STC3141 showed positive signals compared with standard treatment method in terms of alleviating the severity of ARDS, improving the prognosis of ARDS patients, helping ARDS patients to be weaned off the ventilator and shortening the ICU length of stay;
The Phase IIa clinical study of STC3141 for the treatment of severe COVID-19 patients conducted in Europe has also achieved its clinical endpoint, with no serious drug-related adverse reactions, and the patients were well tolerated.